The Alzheimer's community is facing a significant setback as the NHS announces it will not be purchasing Lecanemab, a pioneering treatment for Alzheimer's disease. This decision comes despite clinical trials showing that Lecanemab can slow the progression of the disease and reduce cognitive decline in patients. The annual cost of £10,000 per patient has been deemed too high by the NHS, which operates within a strict £150 billion budget for the current financial year. For Alzheimer's patients and their families, this news is a blow, as they may now be denied access to this potentially life-changing treatment.
According to statistics from the Alzheimer's Society, there are over 900,000 people living with dementia in the UK, with numbers expected to rise to more than 1 million by 2025. The charity estimates that the total cost of dementia in the UK is around £34 billion per year, with the majority of this cost borne by the NHS. This highlights the complexities faced by the NHS when considering high-cost treatments like Lecanemab and balancing the need for effective care within its limited budget.
Nice guidelines recommend that patients with Alzheimer's disease receive a comprehensive diagnosis and treatment plan, which may include medication to manage symptoms. However, at present, Lecanemab is not part of the NHS's standard treatment plan for Alzheimer's disease. Patients interested in learning more about this treatment should speak to their GP or consult the NHS website for information.
The decision not to purchase Lecanemab has sparked a debate on the affordability of high-cost treatments within the UK's healthcare system. The Department of Health and Social Care reaffirms its commitment to making the most of the NHS budget while ensuring patients have access to the best possible care, leaving questions about how such high-cost treatments can be made more accessible in the future.